/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

MONTE ROSA THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$16.86 0.0941(9.41%) GLUE at 04 Dec 2025 04:33 PM Biotechnology
Lowest Today 15.4
Highest Today 16.99
Today’s Open 15.4
Prev. Close 15.41
52 Week High 16.99
52 Week Low 3.50
Day’s Range: Low 15.4 High 16.99
52-Week Range: Low 3.50 High 16.99
1 day return -
1 Week return +4.11
1 month return +40.6
3 month return +243.77
6 month return +264.61
1 year return +81.91
3 year return +80.74
5 year return -
10 year return -

Institutional Holdings

NEA Management Company, LLC 12.46

T. Rowe Price Associates, Inc. 10.24

Bvf Inc 9.16

Versant Venture Management LLC 9.15

Baker Bros Advisors LP 7.96

BlackRock Inc 6.23

venBio Select Advisor LLC 6.03

Suvretta Capital Management, LLC 5.44

Vanguard Group Inc 5.09

US Small-Cap Growth II Equity Comp 4.72

T. Rowe Price New Horizons 4.59

FMR Inc 3.70

Vanguard Total Stock Mkt Idx Inv 3.04

Aisling Capital Management LP 2.38

Alphabet Inc 2.37

HBM Healthcare Investments AG Ord 2.28

AQR Capital Management LLC 2.08

FIAM Small Cap Core CIT Cl B 2.04

Geode Capital Management, LLC 1.82

iShares Russell 2000 ETF 1.78

T. Rowe Price Health Sciences 1.69

T. Rowe Price New Horizons Tr-A 1.46

State Street Corp 1.35

Northern Trust Corp 1.23

Parkwood LLC 1.15

Renaissance Technologies Corp 1.00

Morgan Stanley - Brokerage Accounts 0.92

T. Rowe Price Integrated US SmCapGrEq 0.87

T. Rowe Price Integrated US Sm Gr Eq 0.87

Strategic Advisers Fidelity US TtlStk 0.82

Vanguard Institutional Extnd Mkt Idx Tr 0.79

Royal Bank of Canada 0.76

Fidelity Small Cap Index 0.76

Fidelity Series Small Cap Core 0.68

iShares Russell 2000 Value ETF 0.66

Avantis US Small Cap Value ETF 0.53

Northern Small Cap Value 0.51

NT Quality Small Cap Value 0.51

iShares Biotechnology ETF 0.44

Fidelity Extended Market Index 0.39

Market Status

Strong Buy: 6

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1003.46 M

PB Ratio 4.2831

PE Ratio 49.7097

Enterprise Value 701.86 M

Total Assets 438.73 M

Volume 1317160

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-132882000 -132.9M, FY22:-104618000 -104.6M, FY21:-71942000 -71.9M, FY20:-36068000 -36.1M, FY19:-8017000 -8.0M

Quarterly Revenue Q3/2025:12768000 12.8M, Q2/2025:23194000 23.2M, Q1/2025:84929000 84.9M, Q3/2024:9216000 9.2M, Q2/2024:4695000 4.7M

Quarterly Profit Q3/2025:10673000 10.7M, Q2/2025:23194000 23.2M, Q1/2025:84929000 84.9M, Q3/2024:9216000 9.2M, Q2/2024:2635000 2.6M

Quarterly Net worth Q3/2025:-27081000 -27.1M, Q2/2025:-12295000 -12.3M, Q1/2025:46885000 46.9M, Q3/2024:-23859000 -23.9M, Q2/2024:-30310000 -30.3M

Fund house & investment objective

Company Information Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 147

Industry Biotechnology

CEO Dr. Markus Warmuth M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow